These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38985679)

  • 1. ADP-ribosylome analysis reveals homogeneous DNA-damage-induced serine ADP-ribosylation across wild-type and BRCA-mutant breast cancer cell lines.
    Anagho HA; Mullari M; Prósz AG; Buch-Larsen SC; Cho H; Locard-Paulet M; Szallasi Z; Nielsen ML
    Cell Rep; 2024 Jul; 43(7):114433. PubMed ID: 38985679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
    Yamaguchi H; Du Y; Nakai K; Ding M; Chang SS; Hsu JL; Yao J; Wei Y; Nie L; Jiao S; Chang WC; Chen CH; Yu Y; Hortobagyi GN; Hung MC
    Oncogene; 2018 Jan; 37(2):208-217. PubMed ID: 28925391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serine is the major residue for ADP-ribosylation upon DNA damage.
    Palazzo L; Leidecker O; Prokhorova E; Dauben H; Matic I; Ahel I
    Elife; 2018 Feb; 7():. PubMed ID: 29480802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serine ADP-ribosylation reversal by the hydrolase ARH3.
    Fontana P; Bonfiglio JJ; Palazzo L; Bartlett E; Matic I; Ahel I
    Elife; 2017 Jun; 6():. PubMed ID: 28650317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.
    Gogola E; Duarte AA; de Ruiter JR; Wiegant WW; Schmid JA; de Bruijn R; James DI; Guerrero Llobet S; Vis DJ; Annunziato S; van den Broek B; Barazas M; Kersbergen A; van de Ven M; Tarsounas M; Ogilvie DJ; van Vugt M; Wessels LFA; Bartkova J; Gromova I; Andújar-Sánchez M; Bartek J; Lopes M; van Attikum H; Borst P; Jonkers J; Rottenberg S
    Cancer Cell; 2018 Jun; 33(6):1078-1093.e12. PubMed ID: 29894693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serine-linked PARP1 auto-modification controls PARP inhibitor response.
    Prokhorova E; Zobel F; Smith R; Zentout S; Gibbs-Seymour I; Schützenhofer K; Peters A; Groslambert J; Zorzini V; Agnew T; Brognard J; Nielsen ML; Ahel D; Huet S; Suskiewicz MJ; Ahel I
    Nat Commun; 2021 Jul; 12(1):4055. PubMed ID: 34210965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nucleolytic processing of abasic sites underlies PARP inhibitor hypersensitivity in ALC1-deficient BRCA mutant cancer cells.
    Ramakrishnan N; Weaver TM; Aubuchon LN; Woldegerima A; Just T; Song K; Vindigni A; Freudenthal BD; Verma P
    Nat Commun; 2024 Jul; 15(1):6343. PubMed ID: 39068174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The fast-growing business of Serine ADP-ribosylation.
    Longarini EJ; Matic I
    DNA Repair (Amst); 2022 Oct; 118():103382. PubMed ID: 35963141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An HPF1/PARP1-Based Chemical Biology Strategy for Exploring ADP-Ribosylation.
    Bonfiglio JJ; Leidecker O; Dauben H; Longarini EJ; Colby T; San Segundo-Acosta P; Perez KA; Matic I
    Cell; 2020 Nov; 183(4):1086-1102.e23. PubMed ID: 33186521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
    Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
    Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
    [No Abstract]   [Full Text] [Related]  

  • 11. Specific killing of DNA damage-response deficient cells with inhibitors of poly(ADP-ribose) glycohydrolase.
    Gravells P; Grant E; Smith KM; James DI; Bryant HE
    DNA Repair (Amst); 2017 Apr; 52():81-91. PubMed ID: 28254358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systems-wide Analysis of Serine ADP-Ribosylation Reveals Widespread Occurrence and Site-Specific Overlap with Phosphorylation.
    Larsen SC; Hendriks IA; Lyon D; Jensen LJ; Nielsen ML
    Cell Rep; 2018 Aug; 24(9):2493-2505.e4. PubMed ID: 30157440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive ADP-ribosylome analysis identifies tyrosine as an ADP-ribose acceptor site.
    Leslie Pedrioli DM; Leutert M; Bilan V; Nowak K; Gunasekera K; Ferrari E; Imhof R; Malmström L; Hottiger MO
    EMBO Rep; 2018 Aug; 19(8):. PubMed ID: 29954836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serine ADP-Ribosylation Depends on HPF1.
    Bonfiglio JJ; Fontana P; Zhang Q; Colby T; Gibbs-Seymour I; Atanassov I; Bartlett E; Zaja R; Ahel I; Matic I
    Mol Cell; 2017 Mar; 65(5):932-940.e6. PubMed ID: 28190768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone ADP-ribosylation promotes resistance to PARP inhibitors by facilitating PARP1 release from DNA lesions.
    Zentout S; Imburchia V; Chapuis C; Duma L; Schützenhofer K; Prokhorova E; Ahel I; Smith R; Huet S
    Proc Natl Acad Sci U S A; 2024 Jun; 121(25):e2322689121. PubMed ID: 38865276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
    Oplustilova L; Wolanin K; Mistrik M; Korinkova G; Simkova D; Bouchal J; Lenobel R; Bartkova J; Lau A; O'Connor MJ; Lukas J; Bartek J
    Cell Cycle; 2012 Oct; 11(20):3837-50. PubMed ID: 22983061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serine ADP-ribosylation in Drosophila provides insights into the evolution of reversible ADP-ribosylation signalling.
    Fontana P; Buch-Larsen SC; Suyari O; Smith R; Suskiewicz MJ; Schützenhofer K; Ariza A; Rack JGM; Nielsen ML; Ahel I
    Nat Commun; 2023 Jun; 14(1):3200. PubMed ID: 37268618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
    Madorsky Rowdo FP; Xiao G; Khramtsova GF; Nguyen J; Martini R; Stonaker B; Boateng R; Oppong JK; Adjei EK; Awuah B; Kyei I; Aitpillah FS; Adinku MO; Ankomah K; Osei-Bonsu EB; Gyan KK; Altorki NK; Cheng E; Ginter PS; Hoda S; Newman L; Elemento O; Olopade OI; Davis MB; Martin ML; Bargonetti J
    Cancer Lett; 2024 Mar; 584():216608. PubMed ID: 38199587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
    Clark CC; Weitzel JN; O'Connor TR
    Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status.
    Saravi S; Alizzi Z; Tosi S; Hall M; Karteris E
    Cells; 2021 Sep; 10(9):. PubMed ID: 34572083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.